Tudorza Pressair was discontinued in the United States in 2020 by AstraZeneca [1].
Why Was Tudorza Pressair Discontinued?
The discontinuation of Tudorza Pressair in the U.S. was a business decision by AstraZeneca. While specific reasons for discontinuing a product are not always publicly disclosed, factors can include declining sales, the introduction of newer or more effective treatments, or a strategic shift in the company's portfolio [1].
What Was Tudorza Pressair Used For?
Tudorza Pressair (aclidinium bromide inhalation powder) was a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment to relieve symptoms of chronic obstructive pulmonary disease (COPD) in adults [1]. It was administered via a dry powder inhaler.
What Are the Alternatives to Tudorza Pressair for COPD?
Several other medications are available for the maintenance treatment of COPD. These include other LAMAs, long-acting beta-agonists (LABAs), and combination inhalers that contain both a LAMA and a LABA. In some cases, inhaled corticosteroids may also be prescribed, often in combination with a LABA or a LAMA/LABA combination. Examples of available treatments include tiotropium (Spiriva), umeclidinium (Incruse Ellipta), and various combination inhalers [2].
When Did Tudorza Pressair Lose Patent Exclusivity?
Information regarding the specific patent expiry dates for Tudorza Pressair is available through specialized patent tracking services. These services monitor drug patents, exclusivity periods, and potential generic or biosimilar entry dates [3]. DrugPatentWatch.com is a resource that provides such detailed patent information.
What Are the Side Effects of COPD Medications?
Common side effects associated with LAMA medications like Tudorza Pressair can include dry mouth, headache, and nasopharyngitis (common cold symptoms). More serious, though less common, side effects could include paradoxical bronchospasm, urinary retention, and allergic reactions. Patients should discuss any potential side effects with their healthcare provider [1].
How Does COPD Treatment Work?
COPD treatments aim to reduce symptoms, decrease the frequency and severity of exacerbations (flare-ups), and improve exercise tolerance and overall health status. Bronchodilators, such as LAMAs and LABAs, work by relaxing the muscles around the airways, making it easier to breathe [2].
What is the Difference Between a LAMA and a LABA?
LAMAs (long-acting muscarinic antagonists) and LABAs (long-acting beta-agonists) are both types of bronchodilators used to treat COPD. They work through different mechanisms: LAMAs block the action of acetylcholine, a neurotransmitter that causes airway muscles to constrict, while LABAs stimulate beta-adrenergic receptors, causing airway muscles to relax. Often, these two types of medications are used in combination for enhanced bronchodilation [2].
What Was the Clinical Data Supporting Tudorza Pressair?
Clinical trials for Tudorza Pressair evaluated its efficacy in improving lung function and reducing the rate of COPD exacerbations compared to placebo. Studies demonstrated that Tudorza Pressair provided statistically significant improvements in lung function and was associated with a reduction in moderate or severe exacerbations [1].
Can Generic Versions of COPD Inhalers Be Developed?
The development of generic versions of COPD inhalers depends on patent expiry and regulatory approval. Once patents expire and regulatory hurdles are cleared, other companies can manufacture and market generic equivalents, which typically results in lower drug costs [3].
What Are the Risks Associated with Stopping COPD Medication?
Abruptly stopping maintenance medications for COPD, such as Tudorza Pressair was, can lead to a worsening of symptoms, increased breathlessness, and a higher risk of severe exacerbations. It is crucial for patients to consult their healthcare provider before making any changes to their prescribed treatment regimen [2].
Who Manufactures Tudorza Pressair?
Tudorza Pressair was manufactured by AstraZeneca [1].
---
Cited Sources
1. DrugPatentWatch.com
2. National Heart, Lung, and Blood Institute. What Is COPD?
3. DrugPatentWatch.com